Halozyme (HALO) Loses 9% on Weak Earnings

We recently published 10 Losing Stocks in an Otherwise Optimistic Market. Halozyme Therapeutics Inc. (NASDAQ:HALO) was one of the worst performers on Wednesday.

Halozyme snapped a two-day winning streak on Wednesday, shedding 9.01 percent to finish at $73.23 as investors digested a weak earnings performance in both the fourth quarter and full-year 2025.

In an updated report, Halozyme Therapeutics Inc. (NASDAQ:HALO) said that net income last year fell by 28.6 percent to $317 million from $444 million in 2024, despite revenues surging by 37 percent to $1.396 billion from $1.01 billion year-on-year.

Total revenues were said to be primarily driven by a 52 percent jump in royalties and strong sales from Enhanze partner products.

In the fourth quarter, Halozyme Therapeutics Inc. (NASDAQ:HALO) swung to a net loss of $141.59 million from a $137 million net income in the same period a year earlier, but total revenues increased by 51.6 percent to $451.77 million from $298 million year-on-year.

Looking ahead, Halozyme Therapeutics Inc. (NASDAQ:HALO) is targeting to generate between $1.71 billion and $1.81 billion in revenues this year, as well as  $2 billion in 2028.

Royalty revenues alone are projected at $1.13 billion to $1.17 billion, while adjusted EBITDA is expected to be at $1.125 billion to $1.205 billion. Non-GAAP diluted EPS is pegged at $7.75 to $8.25.

While we acknowledge the potential of HALO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.